KR20210102674A - Composition for preventing or treating oral disease comprising extracts of Stewartia pseudocamellia Maxim. - Google Patents

Abstract

The present invention relates to a composition for preventing or treating oral diseases, containing an extract of Stewartia pseudocamellia. More specifically, the present invention relates to a pharmaceutical composition, a food composition, a quasi-drug composition, and a dental composition for preventing or treating oral diseases, which contains an extract of Stewartia pseudocamellia as an active component.

Description

A composition for preventing or treating oral disease comprising extracts of hollyhock tree, comprising extracts of Stewartia pseudocamellia Maxim.

The present invention relates to a composition for preventing or treating oral diseases, comprising an extract of banyan tree. In more detail, the present invention relates to a pharmaceutical composition for preventing or treating oral disease, a food composition, a quasi-drug composition, and a dental composition comprising an extract of banyan tree as an active ingredient.

Among the diseases related to oral health, dental caries and periodontal disease are oral diseases that occur in various age groups from children to adults and the elderly. causing it to drop.

Dental caries and periodontal disease are bacterial infectious diseases caused by bacteria present in the oral cavity. Oral bacteria receive nutrients through food intake and when the density of bacteria increases, a biofilm called dental biofilm forms on the tooth surface. will form Dental plaque is an adhesive bacterial film formed by attaching more than 700 types of bacteria to a thin film of glycoprotein component attached to the tooth surface.

Because the dental plaque in the oral cavity forms a physically thick layer, penetration of external substances is difficult, and because genetic mutation occurs through cell-to-cell interactions, it has a higher resistance to antibacterial substances than airborne bacteria.

If the dental plaque is not removed properly, it will settle on the tooth surface and turn into tartar over time. If tartar is left unattended, gingival bleeding, edema, and tooth shake due to alveolar bone resorption can occur, which can lead to dental caries and periodontal disease. Periodontal disease is a disease that causes inflammation in the tissues surrounding the teeth, such as the gingiva, alveolar bone, periodontal ligament, and cementum, and is a major cause of tooth loss. has been reported to have

Bacteria related to periodontal disease are Gram-negative anaerobes mainly present in the subgingival gingival plaque, and Porphyromonas gingivalis (Porphyromonas). gingivalis Or P gingivalis ) is representative. Porphyromonas gingivalis (P. gingivalis) has a direct effect on periodontal tissue by decomposing collagen and secreting toxins such as ammonia, hydrogen sulfide, amine, lipopolysaccharide, and the like. In addition, metabolites of P. gingivalis stimulate the biological immune system, and the stimulated humoral and cellular immune systems secrete cytokines such as free radicals and interleukins through various actions to induce gum inflammation. also do

Therefore, in preventing and treating periodontal disease, it is essential to remove the dental plaque. The best way to remove the dental plaque is by brushing your teeth properly, but it is difficult to remove the bacterial film on the occlusal surface of the teeth or the bacterial film on the adjacent surface of the teeth with tooth brushing.

In order to compensate for these shortcomings, the use of oral care products containing dental floss or antibacterial agents is increasing recently. Currently, oral antibacterial agents include chlorhexidine, which is a bisbiguanides, cetylpyridium, benzalkonium chloride, and triclosan, which is a phenolic compound, which is a quaternary ammonium agent. Compound-derived antibacterial agents have been reported to cause discoloration of teeth or soft tissues when used for a long period of time, and the possibility of taste changes have been reported.

Recently, as it has been reported that the extracts of quince, cypress, myrrh, ratania, chamomile, and Indian persimmon have antibacterial action against P. gingivalis , it is harmless to the human body from natural products and has excellent antibacterial activity against oral health materials. Research on development is being actively conducted.

In addition, as a background art of the present invention, a lactic acid bacterium composition having anti-cavity activity is described in Korean Patent Registration No. 10-2001074.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating oral diseases, which is harmless to the human body and contains an extract of Nogak tree having excellent antibacterial activity against oral microorganisms as an active ingredient.

Another object of the present invention is to provide a food composition for preventing or improving oral diseases, which is harmless to the human body and includes an extract of Nogak tree having excellent antibacterial activity against oral microorganisms as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition for preventing or improving oral diseases, which is harmless to the human body and contains an extract of Nogak tree having excellent antibacterial activity against oral microorganisms as an active ingredient.

Another object of the present invention is to provide a dental composition for preventing or improving oral diseases, which is harmless to the human body and includes an extract of Nogak tree having excellent antibacterial activity against oral microorganisms as an active ingredient.

According to one aspect, there is provided a pharmaceutical composition for the prevention or treatment of oral diseases comprising an extract of Nogak tree as an active ingredient.

According to an embodiment, the extract of Nogak tree may be at least one of a branch extract of Nogak tree and an extract of Nogak tree leaf.

According to one embodiment, the extract may be one extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

According to one embodiment, the Nogak tree extract may be a butanol fraction of the ethanol extract.

According to one embodiment, the extract of Nogak tree may be included in an amount of 0.01 to 20% by weight based on the total weight of the composition.

According to one embodiment, the Nogak tree extract may be included at a concentration of 0.2 to 10 mg/ml.

According to one embodiment, the oral disease may be one or more of periodontal disease, dental caries, and bad breath.

According to an embodiment, the periodontal disease may be periodontitis, gingivitis, or a combination thereof.

According to one embodiment, the composition may inhibit the formation of a dental biofilm.

According to one embodiment, Porphyromonas ( Porphyromonas ) It may have an antibacterial effect against the genus bacteria.

According to one embodiment, it can be a formyl fatigue Pseudomonas (Porphyromonas) bacteria belonging to the genus Pseudomonas is formyl fatigue seriously balise (Porphyromonas gingivalis).

According to another aspect, there is provided a food composition for the prevention or improvement of oral diseases comprising an extract of Nogak tree as an active ingredient.

According to another aspect, there is provided a quasi-drug composition for the prevention or improvement of oral diseases comprising the extract of Nogak tree as an active ingredient.

According to another aspect, there is provided a dental composition for preventing or improving oral diseases comprising an extract of Nogak tree as an active ingredient.

According to one embodiment, while being derived from a natural product and harmless to the human body, the oral disease-causing bacteria Porphyromonas gingivalis ( Porphyromonas) gingivalis ) can significantly inhibit the activity, so it is possible to provide a pharmaceutical composition for preventing or treating oral diseases comprising an extract of Nogak tree as an active ingredient that can be usefully used for the prevention or treatment of oral diseases.

According to one embodiment, while being derived from a natural product and harmless to the human body, the oral disease-causing bacteria Porphyromonas gingivalis ( Porphyromonas) gingivalis ) It is possible to significantly inhibit the growth of oral diseases can be provided a food composition for preventing or improving oral diseases comprising an extract of Nogak tree as an active ingredient that can be usefully used for the prevention or improvement of oral diseases.

According to one embodiment, while being derived from a natural product and harmless to the human body, the oral disease-causing bacteria Porphyromonas gingivalis ( Porphyromonas) gingivalis ) can significantly inhibit the activity, so it is possible to provide a quasi-drug composition for preventing or improving oral diseases comprising an extract of Nogak tree as an active ingredient that can be usefully used for the prevention or improvement of oral diseases.

According to one embodiment, while being derived from a natural product and harmless to the human body, the oral disease-causing bacteria Porphyromonas gingivalis ( Porphyromonas) gingivalis ) can significantly inhibit the activity, so it is possible to provide a dental composition for preventing or improving oral diseases comprising an extract of Nogak tree as an active ingredient that can be usefully used for the prevention or improvement of oral diseases.

1 is a photograph showing the results of analysis of the antibacterial activity of Nogak tree extract against oral microorganisms.
Figure 2 is Porphyromonas gingivalis ( Porphyromonas gingivalis ) is a photograph showing the results of analysis of the minimum growth inhibitory concentration (MIC) of the extract of Nogak tree branch.
3 is a view schematically showing a method for preparing an extract and fractions of banyan tree.
Figure 4 is a photograph showing the results of the analysis of antibacterial activity against Porphyromonas gingivalis (Porphyromonas gingivalis) of the extract according to the extraction solvent.
Figure 5 is Porphyromonas gingivalis ( Porphyromonas gingivalis ) is a photograph showing the analysis result of the minimum growth inhibitory concentration (MIC) of the butanol fraction (Buthanol Fr.) of the ethanol extract of Nogak tree.

Since the present invention can apply various transformations and can have various embodiments, specific embodiments will be described in detail in the detailed description. However, this is not intended to limit the present invention to specific embodiments, and it should be understood to include all modifications, equivalents and substitutes included in the spirit and scope of the present invention. In describing the present invention, if it is determined that a detailed description of a related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted. Hereinafter, the present invention will be described in more detail.

In order to better understand the present invention, certain terms are defined herein for convenience. Unless defined otherwise herein, scientific and technical terms used herein shall have the meanings commonly understood by one of ordinary skill in the art. Also, unless the context specifically dictates otherwise, it is to be understood that a term in the singular includes its plural form as well, and a term in the plural form also includes its singular form.

According to one aspect, the present application provides a pharmaceutical composition for the prevention or treatment of oral diseases comprising an extract of Nogak tree as an active ingredient.

Stewartia Pseudocamellia (Stewartia pseudocamelli a Maxim.) is a deciduous tree of the family Theaceae, distributed in Jeollanam-do and Buk-do, Gyeongsangnam-do, and North Gyeongsang Province in Korea. This plant is 7~15 m in height, and the bark of this plant falls into thin pieces and becomes reddish-brown, grayish-white, grayish-brown patterns, and is stained. The flowers are bisexual and bloom white in June-July. Capsules are pentagonal. This plant is known as Stewartia koreana Nakai or Stewartia pseudocamellia Maxim. var. koreana (Nakai) shaped flower cup and called Kim and but also views looking into teuksanjong that kind of a round straight and mainly recorded in Stewartia pseudocamellia Maxim, which is also distributed today in Japan, etc., and another two people in the Stewartia ptero -. petiolata Cheng var . koreana (Rehd.) Sealy is recorded. Because of its large and splendid flowers, it is used for ornamental purposes, and the wood is hard and has beautiful patterns, so it is used for furniture and decorations. It relieves eohyeol from bruises and the related activity due to customs was also studied. As mentioned above, it is recorded that it is effective when there is quadriplegia and pain, whose efficacy is recognized. In addition, it has been reported that the antioxidant, anti-inflammatory, and whitening activity of extracts of Nogak tree.

However, there is nothing known about the prevention, treatment, or amelioration effect of oral diseases by the extracts of banyan tree to date.

The extract of hollywood may be extracted from various organs of natural, hybrid or mutated plants of the hollywood, for example, seeds (seeds), roots, above-ground parts, branches, leaves, flowers, body of fruits, and fruits of hollywood. It can be extracted not only from the bark of the plant but also from plant tissue culture. Although not limited thereto, the Nogak tree extract may be at least one of a Nogak tree branch extract and Nogak tree leaf extract, and the Nogak tree branch extract may be suitable as a composition for oral use.

As used herein, the term "extract" refers to an extraction treatment of the hollyhock tree, but is not limited thereto, an extract obtained by the extraction treatment, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, and a prepared product thereof , purified products or mixtures thereof, and the like, may include extracts of all formulations that can be formed using the extract itself and the extract.

The Nogak tree extract can be prepared using a general extraction method, separation and purification method known in the art. The extraction method is not limited thereto, but methods such as immersion extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction may be used.

Although not limited thereto, the Nogak tree extract may be extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Since the degree of extraction and loss of the active ingredient may be different depending on the organic solvent to be extracted, an appropriate organic solvent may be selected and used. Specifically, the extraction may be performed using water, an organic solvent, or a mixed solvent thereof. More specifically, ethanol may be used, but is not limited thereto.

As used herein, the term “fraction” refers to a result obtained by performing fractionation in order to separate a specific component or a specific group of components from a mixture including various components.

The fractionation method for obtaining the fraction herein is not particularly limited thereto, as long as it can exhibit a preventive or therapeutic effect on oral diseases, but may be performed according to a method commonly used in the art. For example, solvent fractionation performed by treating various solvents, ultrafiltration fractionation performed by passing through an ultrafiltration membrane with a constant molecular weight cut-off value, various chromatography (separation according to size, charge, hydrophobicity or affinity) It may be a chromatographic fractionation method for performing a chromatographic fractionation method, and combinations thereof.

In the present invention, the type of the fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water, distilled water, and alcohol; Non-polar solvents, such as hexane, ethyl acetate, chloroform, and dichloromethane, etc. are mentioned. These may be used alone or in combination of two or more. In the case of using alcohol in the fractionation solvent, preferably C1 to C4 alcohol (methanol, ethanol, propanol, butanol) may be used. The Nogak tree extract may be suitable for prevention, improvement, or treatment of oral diseases in the butanol fraction of the ethanol extract.

In addition, the extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.

The composition herein may be for preventing or treating oral diseases.

As used herein, the term "treatment" is an approach to obtaining beneficial or desirable clinical results, whether for the purposes of the present invention, whether perceptible or not, and whether partial or total, beneficial or desirable clinical results. including, but not limited to, alleviation of symptoms, reduction of the severity of the disease, a stabilized (ie, not getting worse) state of the disease, delaying or reducing the rate of disease progression, amelioration or temporary alleviation and amelioration of the disease state. Accordingly, treatment refers to both therapeutic treatment and prophylactic dimensions, and those that need to be treated include those already having the disease as well as those in which the disease is to be prevented. In addition, it may refer to any action to improve or benefit the symptoms of oral disease by administering the pharmaceutical composition of the present invention to an individual.

As used herein, the term “prevention” refers to any act of inhibiting or delaying a disease using the composition, and the composition may be used in the form of a pharmaceutical composition or a composition for oral hygiene, but is not limited thereto.

As used herein, the term “oral disease” refers to various diseases occurring in the oral region, and the oral region refers to a space in the mouth that is connected from the front lip to the pharynx in the back palate. In the present application, the oral disease is a concept that includes any disease occurring in the oral cavity, regardless of the pathology, and non-limiting examples of the oral disease include dental caries, periodontal disease (periodontitis or gingivitis), toothache, sore throat, bad breath, It is a comprehensive concept including the formation of dental biofilm, and mucosal ulceration in the oral cavity, and more preferably periodontitis, gingivitis, or dental caries caused by P. gingivalis. .

As used herein, the term “periodontal disease” is often referred to as gingivitis, and is divided into gingivitis and periodontitis depending on the severity of the disease. It is a relatively light and quick-recovery form of oral disease. The form limited to the gums, that is, soft tissue, is called gingivitis, and when the inflammation has progressed to the gingiva and alveolar bones, it is called periodontitis. There is a V-shaped gap between the gingiva (gum) and the teeth. Periodontal disease is when bacteria attack the lower gingival part of the gingival sulcus and damage the periodontal ligament and adjacent tissues. As inflammation progresses and more tissue is damaged, the groove develops into a periodontal pocket. As the periodontal pocket deepens, the periodontal ligament becomes inflamed, and Porphyromonas gingivalis. gingivalis ), osteoclast differentiation is promoted by lipopolysaccharide (LPS) secreted by periodontal disease, and alveolar bone loss occurs.

As used herein, the term “halitosis” refers to odors originating from the oral cavity and adjacent organs, and 85 to 90% of bad breath originates from the oral cavity, in particular, from the back of the tongue. The main component of bad breath is volatile sulfur compounds, and 90% of the total amount of volatile sulfur compounds is hydrogen sulfide made from cysteine and methyl mercaptan and dimethyl sulfide made from methionine. These components are mainly produced by protein enzymes secreted by anaerobic bacteria, and the back of the tongue is the most important habitat. This area is not well cleaned by saliva, and there are many small depressions, making it a place where bacteria continue to live. The production of volatile sulfur compounds by anaerobic bacteria is the most important cause of bad breath, but it is also caused by oral diseases such as dental caries, periodontitis, and dry mouth. Many types of anaerobic bacteria are involved in the occurrence of bad breath, and a non-limiting example of the bacteria causing bad breath may include Porphyromonas gingivalis , which secretes many types and large amounts of enzymes.

The composition of the present application is characterized in that it has an antibacterial effect on bacteria of the genus Porphyromonas , and in more detail, Porphyromonas gingivalis has an excellent antibacterial effect on the prevention, improvement, and improvement of oral diseases, Or it may have an effect on treatment.

The pharmaceutical composition of the present disclosure may further include a pharmaceutically acceptable carrier, excipient or diluent, which may include a non-naturally occurring carrier. Specifically, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid ( Poly Lactic Acid), poly-L-lactic acid (poly-L-lactic acid), mineral oil, and the like.

The pharmaceutical composition can be prepared according to conventional methods for preventing and treating oral diseases, including oral dosage forms such as pills, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions. In particular, when the pharmaceutical composition of the present application is for preventing or treating oral diseases, it may have a formulation of a spray for oral cavity, an ointment for oral use, or a varnish for oral use. The carrier may include various amorphous carriers, microspheres, nanofibers, rosin, and the like.

In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract and its fractions, for example, starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin, or the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.

Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

The content of the extract or fractions thereof contained in the pharmaceutical composition of the present application is not limited thereto, but is based on the total weight of the final composition, 0.01 to 100% by weight, 0.01 to 50% by weight, more specifically 0.01 to 20% by weight, More specifically, it may be included in an amount of 0.1 to 10% by weight.

Nogak tree extract or a fraction thereof included in the pharmaceutical composition of the present application is not limited thereto, but may be included in a concentration of 0.2 to 10 mg/ml.

The present application provides a method for preventing or treating oral diseases, comprising administering the pharmaceutical composition to a subject.

Since the pharmaceutical composition of the present application exhibits an effect of preventing or treating oral diseases, the method of the present application comprising administering the same to an individual may be usefully utilized for the prevention or treatment of oral diseases.

As used herein, the term "individual" refers to any animal, including humans, that has or may develop an oral disease, for example, monkey, dog, cat, rabbit, guinea pig, rat, mouse, cow, sheep, pig, goat, bird. , fish, and the like, and as a specific example, may be a mammal including a human, but is not limited thereto.

As used herein, the term "administration" means introducing the composition to an individual by any suitable method, and the administration route may be administered through various routes as long as it can reach a target tissue. Specifically, the pharmaceutical composition of the present application may be administered orally, intravenously, subcutaneously, intradermally, intranasally, intraperitoneally, intramuscularly, transdermally, etc., and if necessary for local treatment, a suitable method including intralesional administration and route. For example, it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebrovascular injection, but is not limited thereto.

As the treatment method of the present application, a pharmaceutical composition comprising an extract of Nogak tree may be administered in a pharmaceutically effective amount.

As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat or prevent a disease at a reasonable benefit/risk ratio applicable to medical treatment or prevention, and the effective dose level depends on the severity of the disease, the activity of the drug, Factors including the age, weight, health, sex, sensitivity of the patient to the drug, the administration time of the composition of the present application used, the route of administration and the rate of excretion of the patient, the duration of treatment, the drug used in combination with or concurrently with the composition of the present application, and It may be determined according to factors well known in the medical field. The pharmaceutical composition of the present application may be administered alone or in combination with a known therapeutic agent for oral diseases. Taking all of the above factors into consideration, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects.

In addition, the dosage of the pharmaceutical composition can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction of the disease, the age, weight, sex, history, or the type of substance used as an active ingredient. For example, the pharmaceutical composition of the present application may be administered at 1 mg/kg to 200 mg/kg, specifically 1 mg/kg to 100 mg/kg, more specifically 20 to 40 mg/kg per adult, The administration frequency of the composition of the present application is not particularly limited thereto, but may be administered once a day or administered several times by dividing the dose. The above dosage does not limit the scope of the present application in any way.

According to another aspect, the present application provides a food composition for the prevention or improvement of oral diseases comprising an extract of Nogak tree as an active ingredient.

The food composition for preventing or improving oral disease of the present application may include an extract or a fraction thereof.

As used herein, the term "improvement" refers to any action that improves or benefits the symptoms of suspected and onset individuals of oral disease to be prevented or treated using a composition comprising an extract or a fraction thereof as an active ingredient.

As used herein, the term "food" refers to dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and ice cream, various soups, beverages, tea, drinks, alcoholic beverages, It includes all foods in the conventional sense, such as vitamin complexes, health functional foods, and the like, and is not limited thereto, as long as it can include the Nogak tree extract of the present application or a fraction thereof. In addition, it may include the form of pills, powders, granules, needles, tablets, capsules, or liquids.

As used herein, the term "health functional food" refers to a food manufactured (including processing) using raw materials or ingredients useful for the human body according to the Health Functional Food Act No. 16295, and 'functionality' means It refers to obtaining useful effects for health purposes such as regulating nutrients or physiological effects on the structure and function of the human body. On the other hand, health food refers to food that has an active health maintenance or promotion effect compared to general food, and health supplement refers to food for the purpose of health supplementation. can be mixed. The health functional food of the present application can be prepared by a method commonly used in the art. It can be manufactured in various forms, and unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long period of time by using food as a raw material, and it can be excellent in portability.

The food composition may be prepared by adding raw materials and components commonly added in the art, and the type is not particularly limited. For example, it may include, as an additional ingredient, various herbal extracts, food-logically acceptable food supplements or natural carbohydrates, such as conventional food, but is not limited thereto.

According to another aspect, the present application provides a quasi-drug composition for the prevention or improvement of oral diseases comprising an extract of Nogak tree as an active ingredient.

Specifically, the quasi-drug composition for preventing or improving oral disease of the present application may include an extract or a fraction thereof.

As used herein, the term "quasi-drug" refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating or preventing diseases of humans or animals, have weak action on the human body or do not directly act on the human body, and Non-machines and similar products, as well as products that are used for sterilization, insecticide and similar purposes for the prevention of infection type, and are used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals It refers to items that are not instruments, machines, or devices, and items that are not used for the purpose of pharmacologically affecting the structure and function of humans or animals, other than those that are not instruments, machines, or devices. In addition, the quasi-drugs may include skin external preparations or personal hygiene products.

The external preparation for skin is not particularly limited thereto, and specifically, it may be prepared and used in the form of ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or gels, and the personal care products include Although not particularly limited thereto, specifically, soap, cosmetics, wet wipes, toilet paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, makeup, foundation, cheek touch, mascara, eye shadow, sunscreen lotion, hair care products , an air freshener gel, or a cleaning gel. In addition, another example of the quasi-drug composition of the present application is a disinfectant cleaner, shower foam, mouthwash, oral spray, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment, or filter filler.

When using the extract or a fraction thereof of the present application as a quasi-drug additive, the extract or fraction can be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and can be used appropriately according to a conventional method, and the active ingredient mixture amount is for the purpose of use may be appropriately determined according to

According to another aspect, the present application provides a dental composition for preventing or improving oral diseases comprising an extract of Nogak tree as an active ingredient.

Specifically, the dental composition for preventing or improving oral diseases of the present application may include an extract or a fraction thereof.

As used herein, the term “dental” may refer to a use for preventing or treating diseases or damage in teeth and their supporting tissues and oral cavity.

The dental composition can be added to fluorine varnish and applied to dental products such as antibacterial fluorine varnish, and oral gargle solution, dental hypersensitivity treatment agent, antibacterial dental adhesive, dental filling material, dental restoration material, dental use. It can be applied to and used in dental materials such as root canal fillers, dental root canal sealers, fissure sealants, dental coatings, and dental cements.

In addition, the dental composition may be used in all articles used for oral health. Examples of the article include dental appliances such as dental floss, toothbrushes, interdental toothbrushes, electric toothbrushes, tongue cleaners, mouthwashes, toothbrush sterilizers, etc., dental devices such as braces and implants, or all dental tools and devices used in dental care. but is not limited thereto.

Specifically, the article is immersed in the dental composition, the dental composition is applied or sprayed on the surface of the article, the surface of the article is washed several times with the dental composition, or the dental composition is permeated. It can be used on the article by a method such as wiping the surface of the article with a towel or the like, and is not particularly limited as long as the article and the dental composition can be in contact for a predetermined period of time. In addition, the time for performing the method is not limited as long as the dental composition can sufficiently react with the surface of the article, and a person skilled in the art can appropriately select it.

Hereinafter, the present invention will be described in more detail by way of Examples. These examples are merely for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited to these examples.

< Example 1> Preparation of extract

After collecting the leaves and branches, the leaves and branches were dried and immersed in 70% ethanol at a ratio of 1:8, followed by room temperature immersion extraction (24 hours) or hot water extraction (1 hour). The extract was concentrated with a rotary evaporator (N-1000SWD; EYELA) at 45° C. to completely remove the solvent, and then dissolved in DMSO (100 mg/ml) and diluted while storing.

< Example 2> Analysis of the antibacterial activity of extracts of banyan tree against oral microorganisms

In order to analyze the antibacterial activity of the extracts of Nogak tree, the antibacterial activity against oral microorganisms was measured.

Streptococcus mutans ( S. mutans ) or Streptococcus sobrinus ( S. sobrinus ) was cultured in Brain Heart Infusion (BHI) broth, Streptococcus sangquinis ( S. sanguinis ), Streptococcus downei (S. downei), Streptococcus anginosus (S. anginosus), Streptococcus gordonii (S. gordonii), Streptococcus criceti (S. criceti) is tryptone yeast extract (TY) ) was incubated. Porphyromonas gingivalis ( Porphyromonas gingivalis ) was used by culturing in Tryptic soy broth (30g/l) supplemented Hemin Solution (final 50 ug/ml), Vitamin K1 solution (final 10 ug/ml). The antibacterial activity of the extract against Porphyromonas gingivalis was determined by the agar diffusion method. Porphyromonas gingivalis gingivalis ) was cultured by placing a paper disc (paper disc, 8 mm diameter, ADVANTEC, Tokyo, Japan) with an extract concentration of 2 mg/disc on the smeared solid medium, and then in the clear zone that appeared around the paper disc. The size was measured and investigated.

The results are shown in Table 1 and FIG. 1 .

As shown in Table 1 and FIG. 1, the extract of Nogak tree exhibits antibacterial activity specifically against P. gingivalis , which is a causative organism such as periodontal disease, dental plaque, or molars, among various oral microorganisms. It was.

<Example 3> Porphyromonas gingivalis ( Porphyromonas gingivalis ) Analysis of the minimum growth inhibitory concentration (MIC) of extract

Porphyromonas gingivalis ( Porphyromonas gingivalis ) In order to measure the antibacterial activity of the extract of yew tree, the minimum growth inhibitory concentration (MIC) for Porphyromonas gingivalis in vitro ( P. gingivalis ) measured.

Porphyromonas gingivalis (P. gingivalis ) was used by culturing in Tryptic soy broth (30g/l) supplemented Hemin Solution (final 50 ug/ml), Vitamin K1 solution (final 10 ug/ml). The minimum growth inhibitory concentration (MIC) of the extract was investigated using a liquid medium dilution method. Porphyromonas gingivalis ( P. gingivalis ) was anaerobically cultured at 37 ° C. for 24 hours, and then the culture medium was diluted in a liquid medium (OD ₆₀₀ =0.4-0.6). After the extract was treated at a concentration of 1, 2, and 3 mg/ml in the diluted culture medium, and then anaerobically cultured at 37 ° C. for 24 hours, the absorbance was measured at 600 nm to determine the proliferation of Porphyromonas gingivalis ( P. gingivalis ). The minimum concentration that does not appear was determined as the minimum growth inhibitory concentration.

The results are shown in Table 2 and FIG. 2 .

As shown in Table 2 and Figure 2, the extract of Porphyromonas gingivalis (P. gingivalis ) from a concentration of 1mg/ml to Porphyromonas gingivalis ( P. gingivalis ) It is found that the growth is inhibited. appear.

<Example 4> Porphyromonas gingivalis ( Porphyromonas gingivalis ) for antibacterial activity assay

After collecting the leaves or branches of cypress trees, extraction was performed with 70% ethanol after drying. The extract was suspended in sterilized distilled water and then an equal volume of n - hexane was added to the (n -hexane) n - fraction with hexane to obtain the water-soluble fraction and a hexane (hexane) fraction (see Fig. 3). The water-soluble fraction chloroform (chloroform), ethyl acetate (ethyl acetate), n - butanol (n -butanol) was added sequentially the chloroform, ethyl acetate, n - butanol, to obtain a water soluble fraction. All fractions were dissolved in DMSO after concentration under reduced pressure, and the antibacterial activity of the fractions against P. gingivalis was determined by a disc diffusion method with a fraction concentration of 1 mg/disc on a paper disc (8 mm). diameter, ADVANTEC, Tokyo, Japan) was confirmed by measuring the size of the clear zone created around the disc after culturing on the solid medium on which the strain was smeared.

The results are shown in Table 3 and FIG. 4 .

As shown in Table 3 and Figure 4, P. gingivalis for P. gingivalis ethanol extract, hexane fraction, chloroform fraction, ethyl acetate fraction, and butanol fraction of the ethanol extract of hollyhock tree all antibacterial activity was confirmed. In particular, it was found that the antibacterial activity of the butanol fraction was the best.

<Example 5> Porphyromonas gingivalis ( P. gingivalis ) Analysis of the minimum growth inhibitory concentration (MIC) of the butanol fraction of the ethanol extract of H.

Porphyromonas gingivalis (P. gingivalis ) was used by culturing in Tryptic soy broth (30g/l) supplemented Hemin Solution (final 50 ug/ml), Vitamin K1 solution (final 10 ug/ml). The minimal inhibitory concentration (MIC) of the extract was investigated using a liquid medium dilution method. Porphyromonas gingivalis ( P. gingivalis ) was anaerobically cultured at 37 ° C. for 24 hours, and then the culture medium was diluted in a liquid medium (OD ₆₀₀ =0.4-0.6). The extract was treated at a concentration of 0.2, 0.4, 0.6, 0.8, 1.0, 2.0 mg/ml in the diluted culture medium, followed by anaerobic culture at 37 ° C. for 24 hours, and then absorbance was measured at 600 nm to measure Porphyromonas gingivalis ( P were positive for at least the concentration of the growth does not appear gingivalis) to the minimum growth inhibitory concentration.

The results are shown in Table 4 and FIG. 5 .

As shown in Tables 4 and 5, the extracts from Porphyromonas gingivalis (P. gingivalis ) showed antibacterial activity from a concentration of 0.4mg/ml, and a concentration-dependent antibacterial activity at 0.4-2mg/ml. appeared to increase.

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims to be described later and their equivalents.

Claims (14)

A pharmaceutical composition for the prevention or treatment of oral diseases comprising an extract of Nogak tree as an active ingredient. The pharmaceutical composition according to claim 1, wherein the Nogak tree extract is at least one of an extract of a branch of Nogak tree and an extract of Nogak tree leaf. The pharmaceutical composition according to claim 1, wherein the Nogak tree extract is extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The pharmaceutical composition of claim 1, wherein the Nogak tree extract is a butanol fraction of the ethanol extract. The pharmaceutical composition according to claim 1, wherein the extract of Nogak tree is included in an amount of 0.01 to 20% by weight based on the total weight of the composition. The pharmaceutical composition according to claim 1, wherein the Nogak tree extract is contained in a concentration of 0.2 to 10 mg/ml. The pharmaceutical composition of claim 1, wherein the oral disease is at least one of periodontal disease, dental caries, and bad breath. The pharmaceutical composition of claim 7, wherein the periodontal disease is periodontitis, gingivitis, or a combination thereof. According to claim 1, wherein the composition inhibits the formation of dental biofilm (dental biofilm), the pharmaceutical composition. According to claim 1, Porphyromonas ( Porphyromonas ) Having an antibacterial effect on bacteria of the genus, the pharmaceutical composition. 11. The method of claim 10, Porphyromonas (Porphyromonas) genus bacteria is Porphyromonas gingivalis (Porphyromonas gingivalis), the pharmaceutical composition. A food composition for the prevention or improvement of oral diseases comprising an extract of Nogak tree as an active ingredient. A quasi-drug composition for the prevention or improvement of oral diseases comprising an extract of Nogak tree as an active ingredient. A dental composition for the prevention or improvement of oral diseases, comprising an extract of Nogak tree as an active ingredient.

Images